Cytological or histological diagnosis of colorectal adenocarcinoma;
KRAS, NRAS, BRAF wild-type;
FcγRIIIaV/V genotype;
stage IV;
age \<75 years;
at least 1 measurable lesion;
ECOG (Eastern Cooperative Oncology Group) Performance Status 0 or 1;
life expectancy\> 3 months;
negative pregnancy test for all potentially childbearing women;
written informed consent.
You may not be if
previous systemic anti-tumor treatment (allowed treatment with capecitabine or fluorouracil and radiotherapy in the neoadjuvant setting of rectal tumors with therapy terminated at least 6 months before);
presence of primary non-treated stenosing colorectal neoplasm;
neutrophils \<2000/mm³ or platelets \<100.000/mm³ or hemoglobin \<9 g/dl;
serum creatinine level\> 1.5 times the maximum normal value;
GOT (glutamic oxaloacetic transaminase) and/or GPT (glutamic pyruvic transaminase) \>5 times the maximum normal value and/or bilirubin level \>3 times the maximum normal value;
previous malignant neoplasms (excluding basal or spinocellular cutaneous carcinoma or in situ carcinoma of the uterine cervix);
active or uncontrolled infections;
other concomitant uncontrolled diseases or conditions contraindicating the study - drugs at clinician evaluation;
